[Drug with a high metabolic activity, cocarnit, in the treatment of diabetic cardiac autonomic neuropathy].
Left ventricular diastolic dysfunction in patients with diabetes is formed in the absence of atherosclerotic changes as a consequence of diabetic cardiac autonomic neuropathy in the early stages of diabetes. Progression of autonomic cardiac neuropathy in cardio-vascular type is associated with the violation of energy supply of cells, protein synthesis, electrolyte exchange, the exchange of trace elements, oxidation reduction processes, oxygen-transport function of blood, so that metabolic therapy is carried out to optimize the processes of formation and energy costs. The drug cocarnit activates processes of aerobic oxidation of glucose, as well as providing regulatory influence on the oxidation of fatty acids. Applying of cocarnit in complex therapy in patients with diabetic cardiac autonomic neuropathy found improvement of left ventricular diastolic function, and positive dynamics in the efferent activity balance of the sympathetic and parasympathetic control of heart rate variability, which provides the regression of clinical symptoms.
S V
SV
Popov
O K
OK
Melekhovets'
N V
NV
Demikhova
L B
LB
Vynnychenko
D000255:Adenosine Triphosphate / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D001341:Autonomic Nervous System / Q000187:drug effects / Q000378:metabolism; D009202:Cardiomyopathies / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004338:Drug Combinations; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000494:pharmacology / Q000627:therapeutic use; D010084:Oxidation-Reduction; D013835:Thiamine Pyrophosphate / Q000494:pharmacology / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology; D014805:Vitamin B 12 / Q000494:pharmacology / Q000627:therapeutic use
D002316:Cardiotonic Agents; D004338:Drug Combinations; D005227:Fatty Acids; D009536:Niacinamide; D000255:Adenosine Triphosphate; D005947:Glucose; D014805:Vitamin B 12; D013835:Thiamine Pyrophosphate